Novel treatment-specific causal biomarkers for colorectal cancer by omics integration.

ABSTRACT: While monoclonal antibody-based targeted therapies have substantially improved progression-free survival in cancer patients, the variability in individual responses poses a significant challenge in patient care. Therefore, identifying cancer subtypes and their associated biomarkers is required for assigning effective treatment. In this study, we integrated genotype and pre-treatment tissue RNA-seq data and identified biomarkers causally associated with the overall survival (OS) of colorectal cancer (CRC) patients treated with either cetuximab or bevacizumab. We performed enrichment analysis for specific consensus molecular subtypes (CMS) of CRC and evaluated differential expression of identified genes using paired tumor and normal tissue from an external cohort. In addition, we replicated

SUBMITTER: Yazdani A 

PROVIDER: S-EPMC12204401 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature